1. Home
  2. COEP vs IOTR Comparison

COEP vs IOTR Comparison

Compare COEP & IOTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • IOTR
  • Stock Information
  • Founded
  • COEP 2017
  • IOTR 2019
  • Country
  • COEP United States
  • IOTR Singapore
  • Employees
  • COEP N/A
  • IOTR N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • IOTR
  • Sector
  • COEP Health Care
  • IOTR
  • Exchange
  • COEP Nasdaq
  • IOTR NYSE
  • Market Cap
  • COEP 32.0M
  • IOTR 29.5M
  • IPO Year
  • COEP N/A
  • IOTR 2025
  • Fundamental
  • Price
  • COEP $8.95
  • IOTR $0.41
  • Analyst Decision
  • COEP
  • IOTR
  • Analyst Count
  • COEP 0
  • IOTR 0
  • Target Price
  • COEP N/A
  • IOTR N/A
  • AVG Volume (30 Days)
  • COEP 28.9K
  • IOTR 671.5K
  • Earning Date
  • COEP 05-14-2025
  • IOTR 01-01-0001
  • Dividend Yield
  • COEP N/A
  • IOTR N/A
  • EPS Growth
  • COEP N/A
  • IOTR N/A
  • EPS
  • COEP N/A
  • IOTR N/A
  • Revenue
  • COEP $62,874.00
  • IOTR $9,578,336.00
  • Revenue This Year
  • COEP N/A
  • IOTR N/A
  • Revenue Next Year
  • COEP N/A
  • IOTR N/A
  • P/E Ratio
  • COEP N/A
  • IOTR N/A
  • Revenue Growth
  • COEP N/A
  • IOTR 13.93
  • 52 Week Low
  • COEP $2.31
  • IOTR $0.31
  • 52 Week High
  • COEP $13.70
  • IOTR $5.98
  • Technical
  • Relative Strength Index (RSI)
  • COEP 45.20
  • IOTR N/A
  • Support Level
  • COEP $9.14
  • IOTR N/A
  • Resistance Level
  • COEP $9.82
  • IOTR N/A
  • Average True Range (ATR)
  • COEP 0.54
  • IOTR 0.00
  • MACD
  • COEP -0.06
  • IOTR 0.00
  • Stochastic Oscillator
  • COEP 21.51
  • IOTR 0.00

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: